Brian Wynne Selected Research

dolutegravir

1/2022	Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
1/2022	Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
1/2022	Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
1/2021	Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
1/2020	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
12/2019	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
1/2018	Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
12/2017	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
1/2016	The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.
12/2015	Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brian Wynne Research Topics

Disease

13	Infections 01/2022 - 10/2002
3	Headache (Headaches) 01/2019 - 12/2017
3	Pneumonia (Pneumonitis) 02/2005 - 10/2002
3	Chronic Bronchitis 01/2005 - 10/2002
2	Nausea 01/2019 - 12/2017
2	HIV Infections (HIV Infection) 01/2018 - 01/2014
2	Dizziness (Lightheadedness) 11/2014 - 11/2013
2	Otitis Media 06/2005 - 01/2004
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2004 - 10/2002
2	Sinusitis 01/2004 - 10/2002
1	Inflammation (Inflammations) 01/2022
1	Atherosclerosis 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Insulin Resistance 01/2021
1	Weight Gain 01/2021
1	Nasopharyngitis 01/2018
1	Osteoporosis 01/2018
1	Chronic Hepatitis C 01/2016
1	Cellulitis 11/2014
1	Hypoglycemia (Reactive Hypoglycemia) 01/2014
1	Sleepiness 11/2013
1	Exanthema (Rash) 11/2013
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2013
1	Communicable Diseases (Infectious Diseases) 01/2013
1	Waterborne Diseases 04/2012
1	Rhinosinusitis 08/2006

Drug/Important Bio-Agent (IBA)

12	dolutegravirIBA 01/2022 - 11/2013
6	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 08/2006 - 10/2002
6	Amoxicillin (Wymox)FDA LinkGeneric 08/2006 - 10/2002
5	Lamivudine (Epivir)FDA Link 01/2022 - 12/2017
5	Pharmaceutical PreparationsIBA 12/2019 - 10/2002
4	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)FDA Link 08/2006 - 10/2002
3	Emtricitabine (Emtriva)FDA Link 12/2021 - 12/2017
3	RNA (Ribonucleic Acid)IBA 12/2021 - 11/2013
3	Tenofovir (Viread)FDA Link 12/2019 - 12/2017
3	Penicillins (Penicillin)FDA Link 08/2006 - 10/2002
3	beta-Lactamases (beta-Lactamase)IBA 08/2006 - 10/2002
2	rilpivirine drug combination dolutegravirIBA 01/2022 - 01/2018
2	Rilpivirine (TMC-278)IBA 01/2022 - 01/2018
2	Integrase InhibitorsIBA 01/2022 - 11/2013
2	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2021 - 11/2013
2	TabletsIBA 01/2018 - 01/2004
2	IntegrasesIBA 12/2017 - 01/2016
2	lamivudine drug combination abacavir FDA Link 12/2015 - 11/2013
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	NucleosidesIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Reverse Transcriptase InhibitorsIBA 01/2022
1	Lipopolysaccharide ReceptorsIBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	FumaratesIBA 12/2021
1	Insulin (Novolin)FDA Link 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	LipidsIBA 01/2021
1	abacavir (Ziagen)FDA Link 12/2017
1	Atazanavir Sulfate (Reyataz)FDA Link 12/2017
1	Ritonavir (Norvir)FDA Link 12/2017
1	daclatasvirIBA 01/2016
1	Organic Cation Transporter 2IBA 01/2016
1	CreatinineIBA 11/2014
1	Alanine Transaminase (SGPT)IBA 11/2014
1	Metformin (Glucophage)FDA LinkGeneric 01/2014
1	HIV IntegraseIBA 01/2014
1	RacivirIBA 11/2013
1	PlasticsIBA 01/2013
1	Biological ProductsIBA 04/2012
1	Azithromycin (Zithromax)FDA LinkGeneric 06/2005
1	Dosage Forms (Dosage Form)IBA 01/2004
1	Anti-Infective Agents (Microbicides)IBA 01/2004
1	Levofloxacin (Levaquin)FDA Link 10/2002
1	Clarithromycin (Biaxin)FDA LinkGeneric 10/2002

Therapy/Procedure

6	Therapeutics 01/2022 - 08/2006
1	Art Therapy 01/2018